Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy....
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/2/291 |
| _version_ | 1797476128667992064 |
|---|---|
| author | Yfat Yahalom-Ronen Noam Erez Morly Fisher Hadas Tamir Boaz Politi Hagit Achdout Sharon Melamed Itai Glinert Shay Weiss Inbar Cohen-Gihon Ofir Israeli Marina Izak Michal Mandelboim Yoseph Caraco Noa Madar-Balakirski Adva Mechaly Eilat Shinar Ran Zichel Daniel Cohen Adi Beth-Din Anat Zvi Hadar Marcus Tomer Israely Nir Paran |
| author_facet | Yfat Yahalom-Ronen Noam Erez Morly Fisher Hadas Tamir Boaz Politi Hagit Achdout Sharon Melamed Itai Glinert Shay Weiss Inbar Cohen-Gihon Ofir Israeli Marina Izak Michal Mandelboim Yoseph Caraco Noa Madar-Balakirski Adva Mechaly Eilat Shinar Ran Zichel Daniel Cohen Adi Beth-Din Anat Zvi Hadar Marcus Tomer Israely Nir Paran |
| author_sort | Yfat Yahalom-Ronen |
| collection | DOAJ |
| description | The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife<sup>®</sup> (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife<sup>®</sup> vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife<sup>®</sup> vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife<sup>®</sup>-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs. |
| first_indexed | 2024-03-09T20:53:36Z |
| format | Article |
| id | doaj.art-79c4459068c048c982dd0dd04b24ee33 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T20:53:36Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-79c4459068c048c982dd0dd04b24ee332023-11-23T22:26:40ZengMDPI AGVaccines2076-393X2022-02-0110229110.3390/vaccines10020291Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human SeraYfat Yahalom-Ronen0Noam Erez1Morly Fisher2Hadas Tamir3Boaz Politi4Hagit Achdout5Sharon Melamed6Itai Glinert7Shay Weiss8Inbar Cohen-Gihon9Ofir Israeli10Marina Izak11Michal Mandelboim12Yoseph Caraco13Noa Madar-Balakirski14Adva Mechaly15Eilat Shinar16Ran Zichel17Daniel Cohen18Adi Beth-Din19Anat Zvi20Hadar Marcus21Tomer Israely22Nir Paran23Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelMagen David Adom, National Blood Services, Ramat Gan 52621, IsraelSheba Medical Center, Central Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan 52621, IsraelHadassah Medical Center, Jerusalem 91120, IsraelDepartment of Pharmacology, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelMagen David Adom, National Blood Services, Ramat Gan 52621, IsraelDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelSchool of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, IsraelDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Biotechnology, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelDepartment of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona 7410001, IsraelThe emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife<sup>®</sup> (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-ΔG-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife<sup>®</sup> vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife<sup>®</sup> vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife<sup>®</sup>-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.https://www.mdpi.com/2076-393X/10/2/291COVID-19SARS-CoV-2variantsVOCvaccineBriLife<sup>®</sup> |
| spellingShingle | Yfat Yahalom-Ronen Noam Erez Morly Fisher Hadas Tamir Boaz Politi Hagit Achdout Sharon Melamed Itai Glinert Shay Weiss Inbar Cohen-Gihon Ofir Israeli Marina Izak Michal Mandelboim Yoseph Caraco Noa Madar-Balakirski Adva Mechaly Eilat Shinar Ran Zichel Daniel Cohen Adi Beth-Din Anat Zvi Hadar Marcus Tomer Israely Nir Paran Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera Vaccines COVID-19 SARS-CoV-2 variants VOC vaccine BriLife<sup>®</sup> |
| title | Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera |
| title_full | Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera |
| title_fullStr | Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera |
| title_full_unstemmed | Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera |
| title_short | Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera |
| title_sort | neutralization of sars cov 2 variants by rvsv δg spike elicited human sera |
| topic | COVID-19 SARS-CoV-2 variants VOC vaccine BriLife<sup>®</sup> |
| url | https://www.mdpi.com/2076-393X/10/2/291 |
| work_keys_str_mv | AT yfatyahalomronen neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT noamerez neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT morlyfisher neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT hadastamir neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT boazpoliti neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT hagitachdout neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT sharonmelamed neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT itaiglinert neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT shayweiss neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT inbarcohengihon neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT ofirisraeli neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT marinaizak neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT michalmandelboim neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT yosephcaraco neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT noamadarbalakirski neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT advamechaly neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT eilatshinar neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT ranzichel neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT danielcohen neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT adibethdin neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT anatzvi neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT hadarmarcus neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT tomerisraely neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera AT nirparan neutralizationofsarscov2variantsbyrvsvdgspikeelicitedhumansera |